BIAF — BIOAFFINITY TECHNOLOGIES, INC. (Healthcare >> Diagnostics & Research)
BIAF FAQ
What is BIAF's ROE?
BIOAFFINITY TECHNOLOGIES, INC. reports a Return on Equity (ROE) of -433.71%.
What is BIAF's dividend yield?
BIOAFFINITY TECHNOLOGIES, INC. offers a dividend yield of 0.00%.
What is BIAF's Deepscope Quality Score?
Deepscope rates BIAF's overall financial quality at 38 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy BIAF?
Deepscope's AI Timing Score for BIAF is 26 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does BIAF belong to?
BIOAFFINITY TECHNOLOGIES, INC. is classified under the Healthcare >> Diagnostics & Research sector on the NASDAQ exchange.
|
USD 1.73
Price
-0.15
(-7.98%)
Day Change
|
|
|---|
BIAF Chất lượng tổng thể của cố phiếu Không tốt ( Chất lượng = 38) và Thời điểm mua ...(Sign In to See)...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
Tỷ lệ ROE tương đối thấp
Tỷ lệ ROA tương đối thấp
Lịch sử ROE tương đối thấp
ROE đang giảm đáng kể
Tăng trưởng ROA hiện tại đang dưới mức tiêu chí của chúng tôi.
Biên lợi nhuận ròng tương đối thấp.
Tốc độ tăng trưởng biên lợi nhuận ròng dưới mức tiêu chí của chúng tôi
Lịch sử Biên lợi nhuận ròng tương đối thấp.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
Chi tiết hơn, sẽ thấy rằng các yếu tố chất lượng Không tốt , Sức khỏe tài chính Không tốt , và khả năng kiếm lợi nhuận Không tốt , ...
| Yếu tố Chất lượng |
|
45% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 96 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 1.73 |
| PBV / Sector |
2.33 / -23.44
|
| Earning Per Share | -3.22 |
| PE / Sector |
N/A / 37.86
|
| PEG or PE/Growth / Sector |
N/A / 1.41
|
| Average 1M Daily Value |
0.37 M
GREAT
|
| Average 1W Daily Value |
0.48 M
GREAT
|
| Yếu tố Kỹ thuật |
|
42% |
| Sức khỏe tài chính |
|
45% |
| Khả năng kiếm lợi nhuận |
|
47% |
| Lợi tức cho nhà đầu tư |
|
4% |
| Chi tiết đăng ký |
| Analyze Date | 2026-06-06 09:08:27 |
| Symbol | BIAF |
| Name | BIOAFFINITY TECHNOLOGIES, INC. |
| Sector | Healthcare >> Diagnostics & Research |
| Market | NASDAQ |
| Listed Shares | 4.53 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 8.53 / 32,142.66 |
| Tin tức, Dự báo ước tính |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 3300 Nacogdoches Road, San Antonio, TX, United States, 78217
Phone: 210 698 5334
Website: https://bioaffinitytech.com
Employees: 57
Description: bioAffinity Technologies, Inc. engages in developing non-invasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis in the United States. The company operates through two segments: Diagnostic Research and Development; and Laboratory Services. The company offers CyPath lung which uses flow cytometry technology to detect and analyze cell populations in a person's sputum, or phlegm, to find characteristics indicative of lung cancer, including cancer and/or cancer-related cells that have shed from a lung tumor. The company has a collaboration with Brooke Army Medical Center to evaluate its proprietary tests under development to identify inflammatory biomarkers for asthma and chronic obstructive pulmonary disease. bioAffinity Technologies, Inc. was incorporated in 2014 and is based in San Antonio, Texas.
ME vs SECTOR Healthcare >> Diagnostics & Research
Click a bubble to view stock details · Bubble size represents market capitalization share
Google